Previous Close | 115.49 |
Open | 115.35 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1200 |
Day's Range | 112.29 - 115.76 |
52 Week Range | 89.67 - 121.64 |
Volume | |
Avg. Volume | 5,252,820 |
Market Cap | 195.104B |
Beta (5Y Monthly) | 0.74 |
PE Ratio (TTM) | 34.49 |
EPS (TTM) | 3.26 |
Earnings Date | Apr 17, 2024 - Apr 22, 2024 |
Forward Dividend & Yield | 2.20 (1.96%) |
Ex-Dividend Date | Apr 12, 2024 |
1y Target Est | 125.74 |
Subscribe to Yahoo Finance Plus to view Fair Value for ABT
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
One family’s verdict in a baby-formula lawsuit brings hope for other families whose newborns developed digestive diseases, though they’re not guaranteed to see the same success.
Reckitt Benckiser Group (RBGLY) shares are taking a noticeable hit after an Illinois jury awarded a mother $60 million in a lawsuit, where she argued one of the British consumer goods company's baby formula brands led to the death of her baby. Yahoo Finance Live reports on Reckitt's declining stock and the broader implications this news is having on Abbott Laboratories (ABT), who also produces baby formula products. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.